Immunome, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
IMNM Nasdaq 2836 immunome.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Immunome, Inc.

Immunome (IMNM) Is Down 6.5% After FDA Clears IND For Novel ADC IM-1340 Trial – Has The Bull Case Changed? - Oct 2nd, 2026 7:10 am
Immunome (IMNM) Stock Looks Near Fair Value As Its 186% Run Continues - Oct 1st, 2026 3:11 am
Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Sep 30th, 2026 5:45 am
Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference - Sep 2nd, 2026 5:45 am
Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update - Aug 11th, 2026 2:02 pm
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 6th, 2026 2:02 pm
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Jul 20th, 2026 5:30 am
What This Immunome Sale Means a Day Before a Big FDA Milestone - Jul 12th, 2026 3:04 pm
Immunome Stock Up 32% in a Month: Here's What You Should Know - Jul 10th, 2026 8:40 am
Immunome Announces U.S. FDA Acceptance of New Drug Application for Varegacestat for the Treatment of Adults with Desmoid Tumors - Jul 8th, 2026 5:30 am
Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-1617, a Potential First-in-Class ADC, in Patients with Advanced Solid Tumors - Jun 11th, 2026 5:30 am
Immunome (IMNM) Is Down 12.7% After Phase 3 Varegacestat Data And FDA NDA Filing - Has The Bull Case Changed? - Jun 4th, 2026 8:13 pm
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting - May 30th, 2026 6:00 am
Barclays initiates oncology-focused biotechs with positive outlook - May 28th, 2026 9:26 am